Story perspectives

Health Canada OKs Zepbound, Reduces Obesity-Related Apnea Interruptions

6/25/2026

Summary

Story summary

Health Canada approved Zepbound for adult obesity-related sleep apnea on June 11.
Zepbound’s tirzepatide, which activates GLP-1 and GIP receptors, is recommended as a weekly injection for patients with BMI 30 kg/m².
Phase 3 trials found tirzepatide cut non-CPAP interruptions by 25 and CPAP-user interruptions by 29 versus placebo.
Dr. Mandeep Singh said the reduction could shift severe cases to milder, warned it does not replace CPAP, and cited nausea and pancreas issues.

1 of 1

Story summary

Health Canada approved Zepbound for adult obesity-related sleep apnea on June 11.
Zepbound’s tirzepatide, which activates GLP-1 and GIP receptors, is recommended as a weekly injection for patients with BMI 30 kg/m².
Phase 3 trials found tirzepatide cut non-CPAP interruptions by 25 and CPAP-user interruptions by 29 versus placebo.
Dr. Mandeep Singh said the reduction could shift severe cases to milder, warned it does not replace CPAP, and cited nausea and pancreas issues.